Patents Examined by Suzanne E. Ziska
  • Patent number: 6051396
    Abstract: A method that produces substantial quantities of a desired polypeptide, by delivering genetic material into insect cells. For example, cloned genes, or gene fragments or, derivates may be defined, utilizing as appropriate vector, into host cells for high level production of high purity protein in substantial quantities.
    Type: Grant
    Filed: May 7, 1993
    Date of Patent: April 18, 2000
    Assignee: The Regents of the University of California
    Inventors: Wen-Hwa Lee, Eva Y.-H. P. Lee
  • Patent number: 6020153
    Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: February 1, 2000
    Assignee: Ciba-Geigy Corporation
    Inventors: Norman Hardman, Laura Lee Gill, Ronald F. J. de Winter, Kathrin Wagner, Christoph Heusser
  • Patent number: 5902880
    Abstract: A transcribed non-naturally occuring RNA molecule comprising a desired RNA molecule, wherein the 3' region of the RNA is able to base-pair with at least 8 bases at the 5' terminus of the same RNA molecule.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: May 11, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: James Thompson
  • Patent number: 5891693
    Abstract: The present invention relates to vectors useful for transforming a lymphoid cell line to glutamine independence. The vectors comprise an active glutamine synthetase (GS) gene as well as a heterologous gene of interest to be expressed. The preferred embodiments encompass vectors wherein the heterologous gene is expressed from a relatively strong promoter and the GS gene is expressed from a relatively weak promoter. In one example, the heterologous gene is operatively linked to the hCMV-MIE promoter and the GS gene is operatively linked to the SV40 early region promoter.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: April 6, 1999
    Assignee: Alusuisse Holdings A.G.
    Inventors: Christopher Robert Bebbington, Geoffrey Thomas Yarranton, Richard H. Wilson
  • Patent number: 5885795
    Abstract: The present invention comprises an endothelial inhibitor and method of use therefor. The endothelial inhibitor is a protein isolated from the blood or urine that is eluted as a single peak from C4-reverse phase high performance liquid chromatography. The endothelial inhibitor is a molecule comprising a protein having a molecular weight of between approximately 38 kilodaltons and 45 kilodaltons as determined by reducing polyacrylamide gel electrophoresis and having an amino acid sequence substantially similar to that of a murine plasminogen fragment beginning at amino acid number 98 of a murine plasminogen molecule.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: March 23, 1999
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O'Reilly, M. Judah Folkman, Kim Lee Sim
  • Patent number: 5880274
    Abstract: A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: March 9, 1999
    Assignee: Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
    Inventors: Hiroaki Maeda, Yasuyuki Eda, Kazuhiko Kimachi, Yoichi Ono, Sachio Tokiyoshi
  • Patent number: 5877397
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: March 2, 1999
    Assignee: GenPharm International Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5859312
    Abstract: The invention provides transgenic non-human animals and transgenic non-human mammalian cells having at least one functionally disrupted lymphocyte transduction locus, particularly a CD4 locus, targeting constructs used to produce such transgenic stem cells and animals, methods and targeting constructs for inactivating or suppressing expression of endogenous lymphocyte transduction gene loci, transgenes encoding heterologous lymphocyte transduction proteins, and nonhuman animals that express a human lymphocyte transduction protein and lack expression of a cognate murine lymphocyte transduction protein.
    Type: Grant
    Filed: July 8, 1996
    Date of Patent: January 12, 1999
    Assignee: The Regents of the University of California
    Inventors: Daniel Littman, Shinichiro Sawada, Nigel Killeen
  • Patent number: 5850002
    Abstract: Genetically engineered animals are described that have lost the expression of a homeobox gene and are missing an organ whose development is regulated by that homeobox gene. Such animals are models for organogenesis and can be used in methods for screening for compounds and gene therapies that restore the function of the missing organ. Other genetically engineered animals are described which express a homeobox gene in cells not normally expressing the gene and exhibit a developmental and/or pathologic condition in those cells. Such animals are models for gain of homeobox function and can be used in methods to screen for compounds and gene therapies that affect the developmental and/or pathologic condition due to the gain of homeobox gene expression.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: December 15, 1998
    Assignee: Washington University
    Inventor: Stanley J. Korsmeyer
  • Patent number: 5850001
    Abstract: The present invention relates to a transgenic non-human mammal, whose germ cells and somatic cells contain a recombinant env gene sequence which is operably linked to a promoter effective for the expression of the gene in the neuronal tissues of the mammal and effective for the simulation of neurological syndromes associated with HIV-1, the gene being introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammal is such that transcription of the env gene may be under the control of a promoter sequence, such as a neuron specific promoter of human neurofilament heavy gene (NFH). The promoter can be synthetic or inducible. The transgenic non-human mammal can be a rodent, such as a mouse.
    Type: Grant
    Filed: July 24, 1996
    Date of Patent: December 15, 1998
    Assignee: Universite de Montreal
    Inventors: Allegria Kessous-Elbaz, Jean Michaud, Fouad Berrada
  • Patent number: 5843708
    Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 1, 1998
    Assignee: CIBA-GEIGY Corporation
    Inventors: Norman Hardman, Laura Lee Gill, Ronald F.J. de Winter, Kathrin Wagner, Christoph Heusser
  • Patent number: 5834589
    Abstract: Target cell specificity of delivery vectors is provided by incorporation of a target cell specific binding domain by the use of any binding domain, which binds specifically to a binding site on the target cell. The binding site may be endogenous to the target cell, provided by engineering the target cell, or a suitable binding site may be associated with the target cell. Target cells may also be associated with a CVR polypeptide to provide specificity for the delivery vector. The association of the CVR polypeptide confers target cell specificity for a second virus host cell range, which specificity differs from the viral host cell range of the endogenous target cell or animal host cell viral receptors. The CVR polypeptide may thus comprise a chimeric virus binding site which binds a second virus env binding domain specific for a second virus host cell range, selected from at least one of the group consisting of amphotropic, polytropic, xenotropic, ecotropic and tissue specific.
    Type: Grant
    Filed: October 7, 1993
    Date of Patent: November 10, 1998
    Assignee: New York University
    Inventors: Daniel Meruelo, Takayuki Yoshimoto
  • Patent number: 5830725
    Abstract: High titre helper-free recombinant retrovirus are produced by (a) growing a transfected host cell, produced by transfecting a eukaryotic host cell with a recombinant vector capable of stable episomal maintenance in the host cell, in a medium under conditions whereby the recombinant vector is stably maintained as an episome in the transfected host cell and transcripts of said vector form, with retroviral gag, pol and env gene products, an infectious retrovirus; and (b) isolating from the medium helper-free infectious retrovirus formed in the transfected host cell. The recombinant vectors comprise (i) a retroviral construct comprising an exogenous gene; (ii) a eukaryotic origin of replication sequence providing a substrate for replicase activity capable of replicating the vector in the host cell; and, (iii) a copy control sequence providing a substrate for a copy control activity capable of maintaining the vector at a stable copy number in the host cell.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 3, 1998
    Assignee: The Board of Trustees for the Leland Stanford Junior University
    Inventors: Garry P. Nolan, Todd Kinsella
  • Patent number: 5827516
    Abstract: A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 27, 1998
    Assignee: President and Fellows of Harvard College
    Inventors: Robert Glen Urban, Roman M. Chicz, Dario A. A. Vignali, Mary Lynne Hedley, Lawrence J. Stern, Jack L. Strominger
  • Patent number: 5817453
    Abstract: Methods for cryopreserving spermatogonia cells are presented.
    Type: Grant
    Filed: May 31, 1996
    Date of Patent: October 6, 1998
    Assignee: University of Pennsylvania
    Inventor: Ralph L. Brinster
  • Patent number: 5814318
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: September 29, 1998
    Assignee: GenPharm International Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5811635
    Abstract: This invention is directed to a chimeric mouse capable of mounting murine cellular and humoral immune response, said chimeric mouse being tolerant of human tissue implanted therein. The chimeric mouse of this invention is capable of developing murine T cells and producing murine IgG antibodies, which T cells and antibodies are tolerant of the human tissue implanted in said mouse, thereby allowing for the challenge of said vaccinated mouse with human-specific pathogens and determining the capacity of the vaccine to protect the cells in said implanted tissue from infection. This invention is also directed to a method for the development of said chimeric mouse, as well as to the use of said chimeric mouse for the screening of vaccines for human-specific pathogens.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: September 22, 1998
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Harris Goldstein, Tobias R. Kollmann
  • Patent number: 5807686
    Abstract: A cell population which is composed of cells bearing the stem cell marker CD34 and which are small in size and have little granulation are obtained by separating low density mononuclear hematopoietic cells according to size and then selecting for CD34.sup.+ cells in the smallest size fraction. The size of the cell population corresponds to that obtained at a flow rate of 25-29 ml/min in a counterflow elutriation method using a rotor equivalent to Beckman JE 5.0 spun at 900.times.g. This population of cells consists essentially of very early progenitor cells and the cells are useful in autologous bone marrow transplantation as well as gene therapy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 15, 1998
    Assignees: Regents of University of Minnesota, Rhone-Poulenc Rorer Pharmaceuticals
    Inventors: John E. Wagner, Jane S. Lebkowski
  • Patent number: 5792845
    Abstract: The present invention comprises an endothelial inhibitor and method of use therefor. The endothelial inhibitor is a protein isolated from the blood or urine that is eluted as a single peak from C4-reverse phase high performance liquid chromatography. The endothelial inhibitor is a molecule comprising a protein having a molecular weight of between approximately 38 kilodaltons and 45 kilodaltons as determined by reducing polyacrylamide gel electrophoresis and having an amino acid sequence substantially similar to that of a murine plasminogen fragment beginning at amino acid number 98 of a murine plasminogen molecule.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: August 11, 1998
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O'Reilly, M. Judah Folkman
  • Patent number: 5789650
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: March 18, 1992
    Date of Patent: August 4, 1998
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay